Effects of the preservative purite® on the bioavailability of brimonidine in the aqueous humor of rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 285-292

  Dong, Jennifer Q ^a   Babusis, Darius M ^a   Welty, Devin F ^a   Acheampong, Andrew A ^a   Tang Liu, Diane ^a   Whitcup, Scott M ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; BRIMONIDINE; EYE DROPS; PRESERVATIVE; PURITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG AQUEOUS HUMOR LEVEL; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PH; RABBIT; SAMPLING;

ANIMALS; AQUEOUS HUMOR; BENZALKONIUM COMPOUNDS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG INTERACTIONS; FEMALE; PRESERVATIVES, PHARMACEUTICAL; QUINOXALINES; RABBITS;

EID: 4243134906     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/1080768041725326     Document Type: Article

References (16)

1. 2-adrenoceptor agonists in glaucoma. In: Alpha 2-Adrenergic Recept, [Colloq.] Lanier, S.M., ed. Amsterdam: Harwood, 1997:179-187.
2. Toris, C.B., Gleason, M.L., Camras, C.B., and Yablonski, M.E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 113:1514-1517, 1995.
3. Palmer, R.M., and Kaufman, H.E. Tear film, pharmacology of eye drops, and toxicity. Curr. Opin. Ophthalmol. 6:11-16, 1995.
4. Katz, L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma. 11:119-126, 2002.
5. Acheampong, A.A., Small, D., and Baumgarten, V.H.L. Improving the safety of brimonidine in rabbit eyes. J. Ocul. Pharmacol. Ther. 18:325-337, 2002.
6. Acheampong, A.A., Shackleton, M., John, B., Burke, J., Wheeler, L., and Tang-Liu, D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug. Metab. Dispos. 30:421-429, 2002.
7. Acheampong, A.A., Small, D., Baumgarten, V.H.L., Welty, D., and Tang-Liu, D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. [erratum] J. Ocul. Pharmacol. Ther. 19:91, 2003.
8. Zar, H. Biostatistical Analysis, 2nd ed. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1974:29-35.
9. Tang-Liu, D., and Burk, P.J. The effect of azone on ocular levobunolol absorption: Calculating the area under the curve and its standard error using tissue-sampling compartments. Pharm. Res. 5:238-241, 1988.
10. Mundorf, T., Williams, R., Whitcup, S., Felix, C., and Batoosingh, A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J. Ocular Pharmacol. Ther. 19:37-44, 2003.
11. Burstein, N.L., and Anderson, J.A. Corneal penetration and aqueous humor concentration of drugs. J. Ocul. Pharmacol. 1:309-326, 1985.
12. Schoenwald, R.D., and Huang, H.S. Corneal penetration behavior of beta-blocking agents I: Physiochemical factors. J. Pharm. Sci. 72:1266-1272, 1983.
13. Kyrronen, K., and Urtti, A. Effects of epinephrine pretreatment and pH on ocular and systemic absorption of ocularly applied timolol in rabbits. J. Pharm. Sci. 79:688-691, 1990.
14. Podder, S.K., Moy, K.C., and Lee, V.H.L. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition. Exp. Eye. Res. 54:747-757, 1992.
15. Sasaki, H., Nagano, T., Yamamura, K., and Nakamura, J. Ophthalmic preservatives as absorption promotors for ocular drug delivery. J. Pharm. Pharmacol. 47:703-707, 1995.
16. Saettone, M.F., Chetoni, P., Carbai, R., Mazzanti, G., and Braghiroli, L. Evaluation of ocular permeation enhancers-in vivo effects on corneal transport of 4 beta-blockers and in vitro-in vivo toxic activity. Int. J. Pharm. 142:103-113, 1996.